DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.
Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Y
Y
Pommier
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001665:Binding Sites; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects; D004260:DNA Repair / Q000187:drug effects; D015195:Drug Design; D004351:Drug Resistance; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors
D000970:Antineoplastic Agents; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D002166:Camptothecin